DENVER, Jan. 27, 2022 /PRNewswire/ -- DaVita Inc. (NYSE:
DVA), announced today that it will hold its quarterly
conference call to discuss fourth quarter results on Thursday, February 10, 2022, at 5:00 p.m. Eastern Time. The company plans to
release its results after market close the same day.
This call is also being webcast and can be accessed at the
DaVita IR web page. You can join this call as follows:
Thursday, February 10, 2022
Starting at 5:00 p.m. EST
Dial in number: 877-918-6630
International dial in: 517-308-9042
Webcast: investors.davita.com
When calling in, please provide the operator the password
"Earnings" and provide your name and company affiliation. Investors
unable to listen to the conference call will be able to access a
replay via our website at investors.davita.com. There will be no
telephone replay.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care
provider focused on transforming care delivery to improve quality
of life for patients globally. The company is one of the largest
providers of kidney care services in the U.S. and has been a leader
in clinical quality and innovation for more than 20 years. DaVita
cares for patients at every stage and setting along their kidney
health journey—from slowing the progression of kidney disease to
helping to support transplantation, from acute hospital care to
dialysis at home. As of September 30, 2021, DaVita served
203,000 patients at 2,822 outpatient dialysis centers
in the United States. The company also operated 333
outpatient dialysis centers in ten countries worldwide. DaVita has
reduced hospitalizations, improved mortality, and worked
collaboratively to propel the kidney care industry to adopt an
equitable and high-quality standard of care for all patients,
everywhere. To learn more, visit DaVita.com/About.
Contact Information
Investors:
Jim Gustafson
jim.gustafson@davita.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/davita-inc-schedules-4th-quarter-2021-investor-conference-call-301470108.html
SOURCE DaVita Inc.